EUCTR2007-001211-33-FR进行中（未招募）1 期
International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyngeal carcinoma (NPC) in children and adolescents
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Histological diagnosis of nasopharyngeal carcinoma WHO type II or III
- •Newly diagnosed disease NPC Stage IIB-IV disease with measurable disease
- •Ages eligible for study: <=18 years of age at time of diagnosis.
- •Genders eligible for study: Both
- •All patients and/or their parents or legal guardians must sign a written informed consent.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients with short life expectancy.
- •Prior chemotherapy or radiotherapy to the nasopharynx or neck for the treatment of nasopharyngeal carcinoma
- •Performance status (Appendix C)
- •- Patients = 16 years of age: Lansky <60%
- •- Patients > 16 years of age: Karnofsky <60%
- •Creatinine clearance or radioisotope glomerular filtration rate (GFR) <70 mL/min OR
- •- Serum creatinine based on age as follows for the calculation of GFR:
- •Greater than 0.8 mg/dL (for patients = 5 years of age)
- •Greater than 1.0 mg/dL (for patients 6-10 years of age)
- •Greater than 1.2 mg/dL (for patients 11-15 years of age)
- •Greater than 1.5 mg/dL (for patients > 15 years of age)
- •Bilirubin > 1.5 times upper limit of normal (ULN) for age
- •AST or ALT > 2.5 times ULN for age
- •Positive pregnancy test
- •Fertile patients unwilling to use effective contraception
- •Refusal or inability to give informed consents to participate in the study
研究者
相似试验
进行中（未招募）
1 期
International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyngeal carcinoma (NPC) in children and adolescents------------------------------------------Estudio aleatorizado internacional para evaluar la suma de docetaxel a la combinación de cisplatino-5-fluoruracilo (TCF) vs. cisplatino-5-fluorouracilo (CF) en el tratamiento de inducción del carcinoma nasofaríngeo (CNF) en niños y adolescentes. - Docetaxel Pediatric study in NPCEUCTR2007-001211-33-ESsanofi-aventis recherche & développement75
进行中（未招募）
不适用
International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyngeal carcinoma (NPC) in children and adolescents - Docetaxel Pediatric study in NPCChildren and adolescents newly diagnosed with NPC with measurable disease T2-T4 any NM, of <18 years of age at the time of diagnosis.MedDRA version: 9.1Level: LLTClassification code 10028793Term: Nasopharyngeal carcinomaEUCTR2007-001211-33-GRsanofi-aventis recherche & développement51
已完成
2 期
A clinical trial to study the effect of Docetaxel when added to standard treatment (Cisplatin and 5-FluroUracil) in Nasopharyngeal Carcinoma in children and adolescents.CTRI/2008/091/000007Sanofi Synthelabo India Limited72
进行中（未招募）
不适用
International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyngeal carcinoma (NPC) in children and adolescents - Docetaxel Pediatric study in NPCEUCTR2007-001211-33-DEsanofi-aventis recherche & développement72
进行中（未招募）
不适用
International randomized study to evaluate the addition of docetaxel to the combination of cisplatin-5-fluorouracil (TCF) vs. cisplatin-5-fluorouracil (CF) in the induction treatment of nasopharyngeal carcinoma (NPC) in children and adolescents - Docetaxel Pediatric study in NPCChildren and adolescents newly diagnosed with NPC Stage IIB-IV with measurable disease, of >1 month to =21 years of age at the time of diagnosis.MedDRA version: 14.1Level: LLTClassification code 10028793Term: Nasopharyngeal carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-001211-33-Outside-EU/EEAsanofi-aventis recherche & développement72